NO20060949L - yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den - Google Patents

yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den

Info

Publication number
NO20060949L
NO20060949L NO20060949A NO20060949A NO20060949L NO 20060949 L NO20060949 L NO 20060949L NO 20060949 A NO20060949 A NO 20060949A NO 20060949 A NO20060949 A NO 20060949A NO 20060949 L NO20060949 L NO 20060949L
Authority
NO
Norway
Prior art keywords
hydrochloride
extracrystalline
avivabradine
preparation
pharmaceutical compositions
Prior art date
Application number
NO20060949A
Other languages
English (en)
Other versions
NO338482B1 (no
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damen
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20060949L publication Critical patent/NO20060949L/no
Publication of NO338482B1 publication Critical patent/NO338482B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)

Abstract

(d-krystalhnsk form av ivabradin-hydroklond med formel (I) kjennetegnet ved dens pulverrøntgendiffraksjonsdiagram Medikamenter
NO20060949A 2005-02-28 2006-02-27 γd-krystallinsk form av ivabradin-hydroklorid, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den NO338482B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501990A FR2882556B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
NO20060949L true NO20060949L (no) 2006-08-29
NO338482B1 NO338482B1 (no) 2016-08-22

Family

ID=34954879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060949A NO338482B1 (no) 2005-02-28 2006-02-27 γd-krystallinsk form av ivabradin-hydroklorid, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den

Country Status (43)

Country Link
US (3) US7361651B2 (no)
EP (1) EP1695709B1 (no)
JP (1) JP4628975B2 (no)
KR (1) KR100827503B1 (no)
CN (1) CN100432057C (no)
AP (1) AP2112A (no)
AR (1) AR056931A1 (no)
AT (1) ATE397933T1 (no)
AU (1) AU2006200855B2 (no)
BR (1) BRPI0600696A (no)
CA (1) CA2537404C (no)
CO (1) CO5770095A1 (no)
CR (1) CR8246A (no)
CU (1) CU23615B7 (no)
CY (1) CY1108220T1 (no)
DE (1) DE602006001411D1 (no)
DK (1) DK1695709T3 (no)
EA (1) EA008532B1 (no)
EC (1) ECSP066376A (no)
ES (1) ES2308688T3 (no)
FR (1) FR2882556B1 (no)
GE (1) GEP20084468B (no)
GT (1) GT200600086A (no)
HK (1) HK1096660A1 (no)
HR (1) HRP20080417T5 (no)
IL (1) IL173960A0 (no)
MA (1) MA28132A1 (no)
ME (2) ME01394B (no)
MY (1) MY157933A (no)
NO (1) NO338482B1 (no)
NZ (1) NZ545579A (no)
PE (1) PE20061070A1 (no)
PL (1) PL1695709T3 (no)
PT (1) PT1695709E (no)
RS (1) RS50600B (no)
SA (1) SA06270041B1 (no)
SG (1) SG125233A1 (no)
SI (1) SI1695709T1 (no)
TW (1) TWI314142B (no)
UA (1) UA81340C2 (no)
UY (1) UY29407A1 (no)
WO (1) WO2006092494A1 (no)
ZA (1) ZA200601760B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2460797A3 (en) 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
EP2162438A4 (en) 2007-05-30 2011-07-06 Ind Swift Lab Ltd PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND CORRESPONDING POLYMORPHIDE
EP2367782B1 (en) 2008-12-22 2013-02-13 KRKA, D.D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
HUE035588T2 (en) 2010-02-12 2018-05-28 Krka D D Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
US9440924B2 (en) 2011-08-02 2016-09-13 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP3156399A1 (en) 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
PT2774606T (pt) 2014-02-14 2019-05-06 Synthon Bv Composição farmacêutica compreendendo polimorfo de cloridrato de ivabradina iv
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534859A (en) * 1895-02-26 Condenser for ice-machines
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DK0547151T3 (da) 1990-08-29 2003-03-17 Humanetics Corp Behandlingsmåde til fremme af vægttab under anvendelse af et substitueret delta-5-androsten
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2818552B1 (fr) 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
US20090318420A1 (en) 2009-12-24
JP4628975B2 (ja) 2011-02-09
HRP20080417T3 (en) 2008-09-30
EA008532B1 (ru) 2007-06-29
UY29407A1 (es) 2006-07-31
AP2112A (en) 2010-03-03
KR100827503B1 (ko) 2008-05-06
BRPI0600696A (pt) 2007-05-08
US7872001B2 (en) 2011-01-18
KR20060095503A (ko) 2006-08-31
AP2006003522A0 (en) 2006-02-28
US7361651B2 (en) 2008-04-22
PL1695709T3 (pl) 2008-10-31
AU2006200855A1 (en) 2006-09-14
FR2882556A1 (fr) 2006-09-01
DE602006001411D1 (de) 2008-07-24
UA81340C2 (en) 2007-12-25
US20080153804A1 (en) 2008-06-26
AU2006200855B2 (en) 2010-12-23
FR2882556B1 (fr) 2007-05-04
CN1827601A (zh) 2006-09-06
CN100432057C (zh) 2008-11-12
GEP20084468B (en) 2008-08-25
NO338482B1 (no) 2016-08-22
JP2006241157A (ja) 2006-09-14
AR056931A1 (es) 2007-11-07
MY157933A (en) 2016-08-15
CR8246A (es) 2008-01-21
ME01394B (me) 2013-12-20
CY1108220T1 (el) 2014-02-12
CU20060038A7 (es) 2008-06-30
DK1695709T3 (da) 2008-09-29
US20060194964A1 (en) 2006-08-31
PT1695709E (pt) 2008-07-04
CA2537404C (fr) 2010-04-13
ECSP066376A (es) 2006-11-16
ATE397933T1 (de) 2008-07-15
ZA200601760B (en) 2008-04-30
HRP20080417T5 (en) 2008-11-30
WO2006092494A1 (fr) 2006-09-08
NZ545579A (en) 2007-01-26
ES2308688T3 (es) 2008-12-01
TW200640871A (en) 2006-12-01
ME02750B (me) 2010-05-07
MA28132A1 (fr) 2006-09-01
SG125233A1 (en) 2006-09-29
CA2537404A1 (fr) 2006-08-28
EP1695709B1 (fr) 2008-06-11
IL173960A0 (en) 2006-07-05
CU23615B7 (es) 2011-01-27
PE20061070A1 (es) 2006-11-18
RS50600B (sr) 2010-05-07
SA06270041B1 (ar) 2010-03-08
GT200600086A (es) 2006-11-02
TWI314142B (en) 2009-09-01
SI1695709T1 (sl) 2008-10-31
EA200600323A1 (ru) 2006-08-25
EP1695709A1 (fr) 2006-08-30
HK1096660A1 (no) 2007-06-08
CO5770095A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
NO20060949L (no) yd-krystallinsk form avivabradin-hydroklorid, fremgangsmate for dens frem5l1lling 0g farmasoytiske sammensetninger inneholdende den
NO20060948L (no) Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064596L (no) Delta-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060946L (no) β-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060947L (no) β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063518L (no) Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
UA97478C2 (ru) Кристаллическая форма vi агомелатина, способ ее приготовления (варианты) и фармацевтическая композиция, которая ее содержит
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
NO20052998L (no) Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
GEP20125547B (en) (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
EP2276729A4 (en) NOVEL TAURINE-DERIVED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
UA93864C2 (ru) Соединения нафталина, способ их получения и фармацевтическая композиция, которая содержит их
JO2501B1 (en) The crystalline form of gamma-D of ivabradine hydrochloride, its preparation process and its pharmaceutical ingredients
NO20065126L (no) D-homo-17-klor-16(17)-en-steroider.
TNSN05077A1 (en) New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
TNSN05076A1 (en) New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
CU23678B7 (es) Procedimiento de preparación de la forma cristalina delta del clorhidrato de la ivabradina y las composiciones farmacéuticas que lo contienen
UY29855A1 (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen